BANK VONTOBEL/CALL/NOVO NORDISK ADR B/170/0.1/20.12.24

BANK VONTOBEL/CALL/NOVO NORDISK ADR B/170/0.1/20.12.24 Share Price

DE000VD1XV34

Market Closed - Boerse Frankfurt Warrants 11:12:03 28/06/2024 pm IST
0.52 ^EUR	-5.45%

1 month	+52.94%
3 months	+4.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart NOVO NORDISK A/S

Chart BANK VONTOBEL/CALL/NOVO NORDISK ADR B/170/0.1/20.12.24

Latest news about NOVO NORDISK A/S

Thinking about trading options or stock in Tesla, Microsoft, Novo Nordisk, Intel, or Solaredge Technologies?	07/02	PR
Thinking about buying stock in NKGen Biotech, Novo Nordisk, SoundHound AI, Safety Shot, or Energy Fuels?	01/02	PR
Thinking about buying stock in Estrella Immunopharma, Novo Nordisk, C4 Therapeutics, Plug Power, or LQR House?	17/01	PR
Thinking about buying stock in Transphorm Technology, Stronghold Digital Mining, Broadcom, Novo Nordisk, or Datadog?	11/01	PR

More news

Quotes 5-day view

Date	Price	Change
28/24/28	0.52	-5.45%
27/24/27	0.55	+1.85%
26/24/26	0.54	-15.62%
25/24/25	0.64	+30.61%
24/24/24	0.49	-.--%

Real-time Boerse Frankfurt Warrants

Last update June 28, 2024 at 11:12 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	NOVO NORDISK A/S
Issuer	Vontobel
WKN	VD1XV3
ISIN	DE000VD1XV34
Date issued	08/03/2024
Strike	170 $
Maturity	20/12/2024 (173 Days)
Parity	10 : 1
Emission price	0.65 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	0.78 €
Lowest since issue	0.24 €
Delta	0.29x
Omega	7.695
Premium	22.89x
Gearing	26.39x
Moneyness	0.8396
Difference Strike	27.26 $
Difference Strike %	+16.04%
Spread	0.01 €
Spread %	1.96%
Theoretical value	0.5050
Implied Volatility	33.50 %
Total Loss Probability	78.14 %
Intrinsic value	0.000000
Present value	0.5050
Break even	175.41 €
Theta	-0.02x
Vega	0.03x
Rho	0.02x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

More about the company